Objective Heart failure with preserved ejection fraction (HFpEF) is a prevalent and clinically
significant condition characterized by limited treatment options. In this context, the objective …

Aims: The efficacy and safety of sacubitril/valsartan for patients with heart failure with
preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the …

Background Compared with angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers, Sacubitril/Valsartan has been reported to have superior results. However …

Background: Sacubitril/valsartan improves heart failure (HF) outcomes in patients with heart
failure with reduced ejection fraction (HFrEF). However, randomized controlled trials (RCTs) …

Aims: The e cacy and safety of sacubitril/valsartan for patients with heart failure with
preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the …

Background Sacubitril-valsartan has a well-established use in reducing mortality and
hospitalisation in heart failure with reduced ejection fraction (HFrEF). It has recently gained …

Background The impact of sacubitril-valsartan on heart failure patients with preserved
ejection fraction (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

Background The impact of sacubitril–valsartan on heart failure (HF) patients with preserved
ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the …

Purpose The objective of this meta-analysis is to determine how sacubitril/valsartan (SV)
compares to equivalent and sub-equivalent angiotensin receptor blockers (ARB) or …